~~<i id='B03AF99033'><strike id='B03AF99033'><tt id='B03AF99033'><pre id='B03AF99033'></pre></tt></strike></i>~~

Home» focus» knowledge

knowledge

author：focus 2025-09-06 03:23:01 Page View：41384

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： AstraZeneca loses challenge to Medicare drug price negotiation
Next article： In Memoriam: Notable people who died in 2023

explore

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Donald Trump's relentless attacks on special counsel Jack Smith

1:24FormerPresidentDonaldTrumpspeakstosupportersatTrumpNationalGolfClubinBedminsterfollowinghisappea

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

KristofferTripplaar/SipaviaAPTheFoodandDrugAdministrationgrantedconditionalapprovalThursdaytothefirs